Log in

Relevant bibliographies by topics / Novel therapeutic drugs

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Novel therapeutic drugs'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Novel therapeutic drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Novel therapeutic drugs"

1

Hashimoto, Kenji. "Editorial:[Novel Therapeutic Drugs for Neuropsychiatric Disorders]." Open Medicinal Chemistry Journal 4, no. 2 (2010): 1–2. http://dx.doi.org/10.2174/1874104501004020001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kehler, Jan, and Jacob Nielsen. "PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia." Current Pharmaceutical Design 17, no. 2 (2011): 137–50. http://dx.doi.org/10.2174/138161211795049624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hirschfield, G. M., M. D. Smith, S. V. Ley, et al. "Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms." Clinical Science 104, s49 (2003): 65P—66P. http://dx.doi.org/10.1042/cs104065pb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kerwin, R., and M. Owen. "Genetics of novel therapeutic targets in schizophrenia." British Journal of Psychiatry 174, S38 (1999): 1–4. http://dx.doi.org/10.1192/s000712500029805x.

Full text

Abstract:

For many years, following the introduction of chlorpromazine in the 1950s, little progress was made in the discovery of new drugs for schizophrenia (Reynolds, 1992). Dopamine D2 receptor blockade was recognised as the only therapeutic target for antipsychotics (Creese et al, 1976) and the inevitable consequences of striatal blockade remained problematic. However, the strategies and stimuli for discovery of new drugs changed with the introduction of new, atypical antipsychotics in the 1990s. These include clozapine, remoxipride (now withdrawn), olanzapine, risperidone and sertindole (Kerwin &am

APA, Harvard, Vancouver, ISO, and other styles

5

Muralidharan, V., and M. Deecaraman. "A Source of Novel Therapeutic Drugs-Marine Actinomycetes." Research Journal of Pharmacy and Technology 10, no. 10 (2017): 3598. http://dx.doi.org/10.5958/0974-360x.2017.00652.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gasparini, Giampietro. "Antiangiogenic drugs as a novel anticancer therapeutic strategy." Critical Reviews in Oncology/Hematology 26, no. 3 (1997): 147–62. http://dx.doi.org/10.1016/s1040-8428(97)10001-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Szallasi, Arpad, Francisco Cruz, and Pierangelo Geppetti. "TRPV1: a therapeutic target for novel analgesic drugs?" Trends in Molecular Medicine 12, no. 11 (2006): 545–54. http://dx.doi.org/10.1016/j.molmed.2006.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Yu, LX, W. Jiang, X. Zhang, et al. "Novel bioequivalence approach for narrow therapeutic index drugs." Clinical Pharmacology & Therapeutics 97, no. 3 (2014): 286–91. http://dx.doi.org/10.1002/cpt.28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Verma, Ujala, R. Sharma, P. Gupta, B. Kapoor, G. Bano, and V. Sawhney. "New uses for old drugs: Novel therapeutic options." Indian Journal of Pharmacology 37, no. 5 (2005): 279. http://dx.doi.org/10.4103/0253-7613.16850.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cunha, Rita F., Sandra Simões, Manuela Carvalheiro, José M. Azevedo Pereira, Quirina Costa, and Andreia Ascenso. "Novel Antiretroviral Therapeutic Strategies for HIV." Molecules 26, no. 17 (2021): 5305. http://dx.doi.org/10.3390/molecules26175305.

Full text

Abstract:

When the first cases of HIV infection appeared in the 1980s, AIDS was a deadly disease without any therapeutic alternatives. Currently, there is still no cure for most cases mainly due to the multiple tissues that act as a reservoir for this virus besides the high viral mutagenesis that leads to an antiretroviral drug resistance. Throughout the years, multiple drugs with specific mechanisms of action on distinct targets have been approved. In this review, the most recent phase III clinical studies and other research therapies as advanced antiretroviral nanodelivery systems will be here discuss

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Novel therapeutic drugs"

1

Gerrard, Stephen Edmund. "A novel infant therapeutic delivery system for drugs, nutrients and anti-viral agents." Thesis, University of Cambridge, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.648462.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Aldughaim, Mohammed. "The use of a novel TIMP3 peptide to specifically target therapeutic drugs to tumours." Thesis, University of Sheffield, 2017. http://etheses.whiterose.ac.uk/19957/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Miller, Mark Russell. "The mechanism of action and therapeutic potential of S-nitrosothiols as novel nitric oxide donor drugs." Thesis, University of Edinburgh, 2003. http://hdl.handle.net/1842/24981.

Full text

Abstract:

Recently, two novel S-nitrosothiols, N-(S-nitroso-<i>N</i>-acetylpenicillamine)-2-amino-2-deoxy-1,3,4,6,tetra-<i>O</i>-acetyl-β-D-glucopyranose (RIG200) and S-nitroso-<i>N</i>-valerylpenicillamine (SNVP), have been described to have selectivity for endothelium-denuded blood vessels. Therefore, they are particularly appealing in the treatment of conditions where the vascular endothelium is damaged. This thesis describes experiments which further elucidate the mechanism of action and therapeutic of these novel S-nitrosothiols, by comparison to conventional NO donors. The key findings were that

APA, Harvard, Vancouver, ISO, and other styles

4

Sunkel, Vanessa Ann. "The investigation of novel marine microorganisms for the production of biologically active metabolites." Thesis, Rhodes University, 2009. http://hdl.handle.net/10962/d1004579.

Full text

Abstract:

New drugs, particularly antibiotics, are urgently required to combat the increasing problem of antibiotic resistant human pathogens. Due to the scarcity of products available today, the pharmaceutical industry is now under pressure to reassess compounds derived from plants, soil and marine organisms. Pharmaceutical companies are showing renewed interest in marine biotechnology as the oceans represent a rich source of both biological and chemical diversity of novel molecular structures with anti-cancer, anti-inflammatory and antibiotic properties. Formerly unexplored locations, such as deep oce

APA, Harvard, Vancouver, ISO, and other styles

5

Khan, Tasmiyah. "Development of a novel, quantitative assay for determining the rate of activity of antimalarial drugs." Thesis, Rhodes University, 2013. http://hdl.handle.net/10962/d1001618.

Full text

Abstract:

Malaria, caused by an intracellular Plasmodium parasite, remains a devastating disease, having claimed approximately 655 000 lives worldwide in 2010. The Medicines for Malaria Venture suggests a "single-dose radical cure" as the ideal malaria treatment since rapid clearance of blood-stage parasites and symptom relief improves patient compliance and limits drug resistance. Thus, novel antimalarials should be rapid-acting and assessing their rate of activity is critical to drug discovery. Traditional evaluation of this rate by morphological assessments is flawed by highly subjective, operator-sp

APA, Harvard, Vancouver, ISO, and other styles

6

Tanner, Delia Caroline. "Over-expression, purification and biochemical characterization of DOXP reductoisomerase and the rational design of novel anti-malarial drugs." Thesis, Rhodes University, 2004. http://hdl.handle.net/10962/d1003990.

Full text

Abstract:

Malaria poses the greatest threat of all parasites to human life. Current vaccines and efficacious drugs are available however their use is limited due to toxicity, emergence of drug resistance, and cost. The discovery of an alternative pathway of isoprenoid biosynthesis, the non-mevalonate pathway, within the malarial parasite has resulted in development of novel anti-malarial drugs. 1-Deoxy-D-xylulose-5-phosphate (DOXP) reductoisomerase, the second enzyme in this pathway, is responsible for the synthesis of 2-C-methyl-D-erythritol 4-phosphate (MEP) in an intramolecular rearrangement step fol

APA, Harvard, Vancouver, ISO, and other styles

7

Wabnitz, Paul Andrew. "Chemistry and medical implications of novel amphibian peptides : a thesis submitted for the degree of Doctor of Philosophy /." Title page, contents and abstract only, 1999. http://web4.library.adelaide.edu.au/theses/09PH/09phw112.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hojati, Ashkhan. "Pharmacologic profiling of novel compounds via fluorometric analyses of monoamine transporter responses." VCU Scholars Compass, 2019. https://scholarscompass.vcu.edu/etd/5983.

Full text

Abstract:

In humans and other organisms, monoaminergic systems are crucial in neuronal function and behavior. The monoamine transporters (MATs), which can be found on the presynaptic plasma membrane of neurons in the central nervous system (CNS), are crucial in the regulation of neurotransmitter concentration in the synaptic cleft. As the duration and concentration of neurotransmitters in the cleft affect further downstream signaling responses, these proteins are important targets for both understanding neuronal physiology and compounds of interest. Multiple theories exist proponing the contribution of

APA, Harvard, Vancouver, ISO, and other styles

9

Cattaneo, Dario. "Therapeutic drug monitoring of novel immunosuppressants." Thesis, Open University, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424822.

Full text

Abstract:

Therapeutic drug monitoring is primarily undertaken for narrow therapeutic inde:drugs, such as immunosuppressants. These drugs have reduced the incidence of acute rejection and improved allograft survival. However, due to their narrow therapeutic index, small variations in blood levels may result in inadequate levels of immunosuppression or toxic drug concentrations. To overcome these problems individual dose regimen based-on phannacokinetic monitoring has been proposed in the past years. Indeed, several studies have previously documented a significant association between cyclosporine whole bl

APA, Harvard, Vancouver, ISO, and other styles

10

Cooper, Remy C. "Novel Therapeutic Delivery via Cell-Nanoparticle Hybridization." VCU Scholars Compass, 2017. http://scholarscompass.vcu.edu/etd/5002.

Full text

Abstract:

The immobilization of surface-modified polyamidoamine (PAMAM) dendrimers on the cell surface introduces a novel approach for efficient and specific cellular uptake of therapeutic-carrying nanoparticles. This cell surface-nanoparticle hybridization event takes place via bioorthogonal copper-free click chemistry between a dibenzocyclooctyne (DBCO) group on the dendrimer surface and azide-capped glycans expressed on the cell membrane through metabolic incorporation of azido sugars. This particular cell-nanoparticle hybridization method can be exploited to deliver a variety of therapeutic, genetic

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Novel therapeutic drugs"

1

Novel therapeutic targets for antiarrhythmic drugs. John Wiley & Sons, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Billman, George Edward. Novel therapeutic targets for antiarrhythmic drugs. John Wiley & Sons, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shukla, Vijay K. Novel antipsychotics for patients with bipolar disorder: A systematic review. Canadian Coordinating Office for Health Technology Assessment, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Shukla, Vijay K. Novel antipsychotics for patients with bipolar disorder: A systematic review. Canadian Coordinating Office for Health Technology Assessment, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Christiansen, Holger, and Nina Merete Christiansen. Progressive neuroblastoma: Innovation and novel therapeutic strategies. Karger, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Cioffi, Christopher L., ed. Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-56619-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tangoing with tornadoes: A novel. Nappy Roots Press, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Development of novel vaccines: Skills, knowledge, and translational technologies. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Miller, Joan Drummond. Beyond bingo: A novel. Creative Arts Book Company, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

National Research Council (U.S.). Committee on New Directions in the Study of Antimicrobial Therapeutics: New Classes of Antimicrobials. Treating infectious diseases in a microbial world: Report of two workshops on novel antimicrobial therapeutics. National Academies Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Novel therapeutic drugs"

1

Lin, Kai. "Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV." In Antiviral Drugs. John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9780470929353.ch22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lupher Jr., Mark L., and W. Scott Willett. "Serum amyloid P: A novel antifibrotic agent with therapeutic potential." In New Drugs and Targets for Asthma and COPD. KARGER, 2010. http://dx.doi.org/10.1159/000320829.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gillard, J. W., R. Dixon, D. Ethier, et al. "Therapeutic potential of 5-lipoxygenase inhibitors: the discovery and development of MK-886, a novel-mechanism leukotriene inhibitor." In Side-Effects of Anti-Inflammatory Drugs 3. Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-2982-4_33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ayodele, Olubukola, and Lillian L. Siu. "New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_23.

Full text

Abstract:

AbstractChemotherapy has been the backbone for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RMNPC), which remains an incurable disease. Currently the most active area of therapeutic investigations in RMNPC is in immunotherapy, especially after the results of five anti-programmed death-1 (anti-PD-1) antibodies, i.e. pembrolizumab, nivolumab, camrelizumab, toripalimab and tislelizumab, have demonstrated monotherapy objective response rates of 21%–43%. Combinations using anti-PD1/L1 antibodies as backbone to evaluate their additivity or synergy with cytotoxic chemotherapy, molecularly targeted agents, or other immuno-oncology compounds are actively being developed. Besides immune checkpoint blockade, additional ways to modulate the host immune system, such as Epstein-Barr virus (EBV)-directed vaccination against viral antigens (such as EBNA1, LMP1, LMP2) with dendritic cells or peptides, adoptive cell transfer of autologous or HLA-matched allogeneic EBV-specific cytotoxic T lymphocytes, CAR or TCR T-cell therapy, personalized cancer vaccines and oncolytic viruses are being explored. Finally, novel molecularly targeted agents that have entered human testing in RMNPC include apatinib and anlotinib (antiangiogenic agents), MAK683 (an embryonic ectoderm development or EED protein inhibitor), among others. This review provides an update of ongoing clinical trials evaluating these new compounds in RMNPC.

APA, Harvard, Vancouver, ISO, and other styles

5

Magnani, John L. "Glycomimetic Drugs: Source of Novel Therapeutics." In Glycoscience: Biology and Medicine. Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54841-6_201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Berman, Cindy L., Scott A. Barros, Sheila M. Galloway, et al. "Genotoxicity Tests for Novel Oligonucleotide-Based Therapeutics." In Oligonucleotide-Based Drugs and Therapeutics. John Wiley & Sons, Inc., 2018. http://dx.doi.org/10.1002/9781119070153.ch10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Patel, Rakesh P., Pranav Shah, Kalyani Barve, Nikunjana Patel, and Jaimini Gandhi. "Peyer’s Patch: Targeted Drug Delivery for Therapeutics Benefits." In Novel Drug Delivery Technologies. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3642-3_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Von Hoff, Daniel D., Elizabeth R. Campbell, and David J. Bearss. "Novel Therapeutic Targets for Drug Development." In Pancreatic Cancer. Springer New York, 2002. http://dx.doi.org/10.1007/0-387-21600-6_38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Magnani, John L. "Glycomimetic Drugs: A Source of Novel Therapeutics." In Glycoscience: Biology and Medicine. Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54836-2_201-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Surti, Naazneen, Ashok Mahajan, and Jitendra Amrutiya. "Colonic Drug Delivery Systems as Multiunit Potential: Therapeutic Strategies and Opportunities." In Novel Drug Delivery Technologies. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3642-3_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Novel therapeutic drugs"

1

Liedtke, C., K. Yan, Y. Wu, et al. "Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-2119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lueshen, Eric, Indu Venugopal, and Andreas Linninger. "Intrathecal Magnetic Drug Targeting: A New Approach to Treating Diseases of the Central Nervous System." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93117.

Full text

Abstract:

Intrathecal (IT) drug delivery is a standard technique which involves direct injection of drugs into the cerebrospinal fluid (CSF)-filled space within the spinal canal to treat many diseases of the central nervous system. Currently, in order to reach the therapeutic drug concentration at certain locations within the spinal canal, high drug doses are used. With no method to deliver the large drug doses locally, current IT drug delivery treatments are hindered with wide drug distributions throughout the central nervous system (CNS) which cause harmful side effects. In order to overcome the curre

APA, Harvard, Vancouver, ISO, and other styles

3

Hirasawa, Akira, Astrid Murumägi, Mariliina Arjama, et al. "Abstract 5384: Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-5384.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sarker, Sunandita, Yiannis S. Chatzizisis, Srivatsan Kidambi, and Benjamin S. Terry. "Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis." In 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6869.

Full text

Abstract:

Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations

APA, Harvard, Vancouver, ISO, and other styles

5

Chen, Kok Hao, and Jong Hyun Choi. "Nanoparticle-Aptamer: An Effective Growth Inhibitor for Human Cancer Cells." In ASME 2009 International Mechanical Engineering Congress and Exposition. ASMEDC, 2009. http://dx.doi.org/10.1115/imece2009-11966.

Full text

Abstract:

Semiconductor nanocrystals have unique optical properties due to quantum confinement effects, and a variety of promising approaches have been devised to interface the nanomaterials with biomolecules for bioimaging and therapeutic applications. Such bio-interface can be facilitated via a DNA template for nanoparticles as oligonucleotides can mediate the aqueous-phase nucleation and capping of semiconductor nanocrystals.[1,2] Here, we report a novel scheme of synthesizing fluorescent nanocrystal quantum dots (NQDs) using DNA aptamers and the use of this biotic/abiotic nanoparticle system for gro

APA, Harvard, Vancouver, ISO, and other styles

6

Nogueira-Recalde, U., F. J. Blanco, M. I. Loza, et al. "SAT0053 Identification of novel drugs with senolytic activity as osteoarthritis therapeutics." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3680.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Krishnan, Rajeev S., Frederick Luk, R. D. Brown, Y. L. Kwan, and Mary Bebawy. "Abstract B52: A novel personalized therapeutic management in multiple myeloma." In Abstracts: AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; June 18-21, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.pms14-b52.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

McMahon, Nathan P., Allison Solanki, Lei G. Wang, et al. "TRIPODD: a novel fluorescence imaging platform for in situ measurement of drug distribution and proteomic therapeutic response." In Visualizing and Quantifying Drug Distribution in Tissue V, edited by Conor L. Evans and Kin Foong Chan. SPIE, 2021. http://dx.doi.org/10.1117/12.2582773.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Karsa, M., T. Failes, GM Arndt, et al. "PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chugh, Rohit, Satish Patil, Veena Sangwan, Selwyn Vickers, Gunda Georg, and Ashok K. Saluja. "Abstract 1771: Therapeutic management of pancreatic cancer using a novel drug, Minnelide." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1771.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Novel therapeutic drugs"

1

Paul, Satashree. Turning Back the Sickle Cell Disease: A New Drug into Play. Science Repository OÜ, 2021. http://dx.doi.org/10.31487/sr.blog.38.

Full text

Abstract:

Researchers at the Fulcrum Therapeutics developed a bioavailable drug candidate called FTX 6058 – (a novel small molecular fetal haemoglobin inducer for sickle cell disease) that can restore the body’s ability to produce fetal haemoglobin

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!